Sahajanand Medical Technologies posted a revenue of Rs 373.41 crore for the quarter ending September 2026, marking growth over the previous year. The company also announced a strategic investment of USD 7.80 lakh in US-based SNP Medical Corp to expand its product portfolio.
Sahajanand Medical Technologies Reports Q2 Performance and Strategic US Investment
Revenue from operations reached Rs 37,341.01 Lakhs for the quarter ended September 30, 2026.
Net profit for the period stood at Rs 2,646.92 Lakhs compared to Rs 2,090.77 Lakhs in the year-ago period.
Reader Takeaway: Revenue growth and international expansion via SNP Medical investment drive sentiment, balanced by related-party transaction scrutiny.
What just happened
Sahajanand Medical Technologies released its unaudited standalone and consolidated financial results for the quarter ending September 30, 2026. The company reported a significant uptick in both revenue and profitability. Alongside these results, the board approved an additional investment of up to USD 7,80,000 in its US-based entity, SNP Medical Corp., through its wholly-owned subsidiary, SMT Ireland.
Why this matters
The investment in SNP Medical Corp is part of a broader strategy to diversify the company's existing product portfolio. By increasing its stake from 14.15% to 17.19%, the firm aims to strengthen its presence in international markets. Shareholders should note that Ms. Priyanka Cohen, a promoter and Non-Executive Director at Sahajanand Medical, is also a director at SNP Medical Corp, making this a related-party transaction conducted on an arm's length basis.
Governance Update
The company has appointed M/s Amit Jaste & Associates as its new Secretarial Auditor. The appointment is for a five-year term covering FY 2026-27 to FY 2030-31, pending formal approval from shareholders at the upcoming general meeting.
Context Metrics (Consolidated)
- Revenue from Operations: Rs 37,341.01 Lakhs (Q2 FY27) vs Rs 29,947.09 Lakhs (Q2 FY26).
- Basic EPS: Rs 2.63 (Q2 FY27) vs Rs 2.00 (Q2 FY26).
- Total Income: Rs 37,564.59 Lakhs (Q2 FY27) vs Rs 30,181.42 Lakhs (Q2 FY26).
What to track next
Investors should monitor the completion of the SNP Medical acquisition, expected by March 31, 2027, and the upcoming shareholder vote regarding the appointment of the new secretarial auditor.